10th Nov 2025 04:32
(Alliance News) - AstraZeneca PLC on Sunday announced results from the phase 3 trial of its Baxdrostat treatment which showed a statistically significant reduction in the systolic blood pressure of patients with resistant hypertension.
The Cambridge, England-based pharmaceutical company said the trial showed patients treated with Baxdrostat demonstrated a "highly clinically meaningful reduction" in average systolic blood pressure compared with a placebo after 12 weeks.
Efficacy was observed throughout the 24-hour period, including early morning, when patients with hypertension are at a higher risk of cardiovascular events.
Sharon Barr, executive vice president of BioPharmaceuticals R&D at AstraZeneca, said: "Patients with elevated night-time blood pressure are especially vulnerable to cardiovascular events, including heart attack and stroke.
"These findings demonstrate the potential of Baxdrostat to redefine what is possible for the millions of patients whose hypertension remains uncontrolled despite current therapies."
Baxdrostat is designed to lower blood pressure by specifically inhibiting aldosterone, a key hormone that raises blood pressure and increases the risk of heart and kidney problems.
AstraZeneca said there were 1.4 billion people worldwide living with hypertension and in the US, approximately 50% of patients living with hypertension on multiple treatments did not have their blood pressure under control.
Shares in AstraZeneca closed 0.4% higher at 12,880.00 pence in London on Friday.
By Lachlan Colquhoun, Alliance News reporter Asia-Pacific
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca